Does EPCORITAMAB-BYSP Cause Diffuse large b-cell lymphoma recurrent? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with EPCORITAMAB-BYSP. This represents 1.3% of all adverse event reports for EPCORITAMAB-BYSP.
13
Reports of Diffuse large b-cell lymphoma recurrent with EPCORITAMAB-BYSP
1.3%
of all EPCORITAMAB-BYSP reports
7
Deaths
3
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From EPCORITAMAB-BYSP?
Of the 13 reports, 7 (53.8%) resulted in death, 3 (23.1%) required hospitalization, and 1 (7.7%) were considered life-threatening.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EPCORITAMAB-BYSP. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does EPCORITAMAB-BYSP Cause?
Cytokine release syndrome (369)
Diffuse large b-cell lymphoma (206)
Diffuse large b-cell lymphoma refractory (198)
Pyrexia (79)
Immune effector cell-associated neurotoxicity syndrome (77)
Covid-19 (39)
Neutrophil count decreased (35)
Hypogammaglobulinaemia (32)
Platelet count decreased (32)
Cytomegalovirus infection (31)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which EPCORITAMAB-BYSP Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
EPCORITAMAB-BYSP vs EPERISONE
EPCORITAMAB-BYSP vs EPHEDRINE
EPCORITAMAB-BYSP vs EPINASTINE
EPCORITAMAB-BYSP vs EPINEPHRINE
EPCORITAMAB-BYSP vs EPINEPHRINE\LIDOCAINE